Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review

• Published in: Expert review of vaccines Vol. 22; no. 1; pp. 35 - 53
• Main Authors: Sandoval, Cristian, Guerrero, Daniela, Muñoz, Joham, Godoy, Karina, Souza-Mello, Vanessa, Farías, Jorge
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 31.12.2023; Taylor & Francis Group
• Subjects: Adolescent; Antibodies, Viral; Coronavirus; COVID vaccines; COVID-19 - prevention & control; COVID-19 Vaccines - adverse effects; Humans; Immunogenicity, Vaccine; number of doses; Protein Subunits; RNA, Messenger; SARS-CoV-2; vaccination; vaccine efficacy; vaccine platforms; Vaccines, Subunit - adverse effects; Viral Vaccines; COVID vaccines; Coronavirus; vaccine efficacy; vaccine platforms; number of doses; vaccination
• ISSN: 1476-0584; 1744-8395; 1744-8395
• DOI: 10.1080/14760584.2023.2156861

Vaccines prevent disease and disability; save lives and represent a good assessment of health interventions. Several systematic reviews on the efficacy and effectiveness of COVID-19 vaccines have been published, but the immunogenicity and safety of these vaccines should also be addressed. This systemic investigation sought to explain the efficacy, immunogenicity, and safety of new vaccination technologies against SARS-CoV-2 in people over 18 years old. Original research studying the effectiveness on mRNA, protein subunit vaccines, and viral vector vaccines against SARS-CoV-2 in people over 18 years old was analyzed. Several databases (Web of Science, Scopus, MEDLINE and EMBASE) were searched between 2012 and November 2022 for English-language papers using text and MeSH terms related to SARS-CoV-2, mechanism, protein subunit vaccine, viral vector, and mRNA. The protocol was registered on PROSPERO, CRD42022341952. Study quality was assessed using the NICE methodology. We looked at a total of six original articles. All studies gathered and presented quantitative data. Our results suggest that new vaccinations could have more than 90% efficacy against SARS-CoV-2, regardless of the technology used. Furthermore, adverse reactions go from mild to moderate, and good immunogenicity can be observed for all vaccine types.